Drug-eluting stents

Chronic Ischemic cardiopathy

PCI with everolimus eluting stent or CABG for multivessel coronary artery disease.

Original title: Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease. Reference: Sripal Bangalore, M.D. et al. N Engl J...

solaci - 9 April, 2015

Chronic Ischemic cardiopathy

Bioresorbable vascular scaffold vs. the best-in-class DES

Original title: Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Referencia: Puricel S. et al. J...

solaci - 1 April, 2015

Coronary disease

Paclitaxel coated balloon catheter vs. DES for DES instent restenosis

Original title: Paclitaxel – coated balloon catheter compared with drug- eluting stent for drug-eluting stent restenosis in routine...

solaci - 12 March, 2015

Antithrombotic Anticoagulants

Zotarolimus eluting stent with one month of dual antiplatelet therapy

Original title: Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Reference: Marco Valgimigli et al. J Am Coll Cardiol....

solaci - 25 February, 2015

Chronic Ischemic cardiopathy

Safety and efficacy of DES in saphenous vein bypass graft PCI

Original title: Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions:...

solaci - 2 February, 2015

Antithrombotic Anticoagulants

Never ending controversy over the duration of post DES dual antiplatelet therapy

Original title: Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy- The SECURITY...

solaci - 15 January, 2015

Antithrombotic Anticoagulants

Risks and benefits of Dual Antiplatelet beyond the year of a drug-eluting stent

Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. Reference: Laura Mauri et al....

solaci - 13 January, 2015

Coronary disease

Lower Rates of In-Stent Thrombosis with the New Generation DES

Original title: New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL...

solaci - 30 October, 2014

PCI with everolimus eluting stent or CABG for multivessel coronary artery disease.

Bioresorbable vascular scaffold vs. the best-in-class DES

Paclitaxel coated balloon catheter vs. DES for DES instent restenosis

Zotarolimus eluting stent with one month of dual antiplatelet therapy

Safety and efficacy of DES in saphenous vein bypass graft PCI

Never ending controversy over the duration of post DES dual antiplatelet therapy

Risks and benefits of Dual Antiplatelet beyond the year of a drug-eluting stent

Lower Rates of In-Stent Thrombosis with the New Generation DES

Últimas Noticias

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Noticias Institucionales

SOLACI Wishes You Happy Holidays

Condolences on the passing of Cristiam Arancibia

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Accesos